Oral serotonin receptor agonists: A review of their cost effectiveness in migraine

PharmacoEconomics

Volumn 23, Issue 3, 2005, Pages 259-274

  Lofland, Jennifer H ^a   Nash, David B ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALMOTRIPTAN; ELETRIPTAN; FROVATRIPTAN; NARATRIPTAN; RIZATRIPTAN; SEROTONIN 1B AGONIST; SEROTONIN 1D AGONIST; SEROTONIN AGONIST; SUMATRIPTAN; ZOLMITRIPTAN;

CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISABILITY; DRUG CLASSIFICATION; HEALTH CARE COST; HUMAN; META ANALYSIS; MIGRAINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SOCIETY; SYSTEMATIC REVIEW;

COST-BENEFIT ANALYSIS; HUMANS; MIGRAINE DISORDERS; SEROTONIN AGONISTS; SUMATRIPTAN;

EID: 18644376733     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200523030-00006     Document Type: Review

References (52)

1. Linet MS, Stewart WF, Celentano DD, et al. An epidemiologic study of headache among adolescents and young adults. JAMA 1989; 261 (15): 2211-6
2. Lipton RB, Stewart WF, Celentano DD, et al. Undiagnosed migraine headaches: a comparison of symptom-based and reported physician diagnosis. Arch Intern Med 1992; 156: 1273-8
3. Lipton RB, Silberstein SD, Stewart WF. An update on the epidemiology of migraine. Headache 1994; 34: 319-28
4. Stewart WF, Lipton RB, Celentano DD. Prevalence of migraine headache in the United States. JAMA 1992; 267: 64-9
5. Hu XH, Markson LE, Lipton RB, et al. Burden of migraine in the united States: disability and economic costs. Arch Intern Med 1999; 159: 813-8
6. Badia X, Magaz S, Gutierrez L, et al. The burden of migraine in Spain: beyond direct costs. Pharmacoeconomics 2004; 22 (9): 591-603
7. Bigal ME, Rapoport AM, Bordini CA, et al. Burden of migraine in Brazil: estimate of cost of migraine to the public health system and an analytical study of the cost-effectiveness of a stratified model of care. Headache 2003 Jul-Aug; 43 (7): 742-54
8. Osterhaus JT, Gutterman DL, Plachetka JR. Healthcare resource and low labour costs of migraine headaches in the US. Pharmacoeconomics 1992; 2 (1): 2-11
9. Ramadan NM, Silberstein SD, Freitag F, et al. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management for Prevention of Migraine. AAN Headache Guidelines: multispecialty consensus on diagnosis and treatment of headache, St Paul, Minnesota: American Academy of Neurology 2000 [online]. Available from URL: http://www.aan.com/public/ practiceguidelines/headache_gl.htm [Accessed 2003 Jul 22]
10. Schulman EA, Cady RK, Henry D, et al. Effectiveness of sumatriptan in reducing productivity loss due to migraine: results of a randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc 2000 Aug; 75 (8): 782-9
11. Mushet GR, Miller D, Clements B, et al. Impact of sumatriptan on workplace productivity, nonwork activities, and health-related quality of life among hospital employees with migraine. Headache 1996; 36 (3): 137-43
12. Cohen JA, Beall D, Beck A, et al. Sumatriptan treatment for migraine in a health maintenenace organization: economic, humanistic, and clinical outcomes. Clin Ther 1999; 21 (1): 190-205
13. Adelman JU, Sharfman M, Johnson R, et al. Impact of oral sumatriptan on workplace productivity, health-related quality of like, healthcare use, and patient satisfaction with medication in nurses with migraine. Am J Managed Care 1996; 2 (10): 1407-16
14. Cohen JA, Beall DG, Miller DW, et al. Subcutaneous sumatriptan for the treatment of migraine: humanistic, economic, and clinical consequences. Fam Med 1996; 28 (3): 171-7
15. Jhingran P, Cady RK, Rubino J, et al. Improvements in health-related quality of life with sumatriptan treatment for migraine. J Med Econ 1996; 42 (1): 36-42
16. Solomon GD, Nielsen K, Miller D. The effects of sumatriptan on migraine: health-related quality of life. Med Interface 1995 Jun;: 134-41
17. Solomon GD. Quality-of-life assessment in patients with headache. Pharmacoeconomics 1994 Jul; 6 (1): 34-41
18. Cady RC, Ryan R, Jhingran P, et al. Sumatriptan injection reduces productivity loss during a migraine attack. Arch Intern Med 1998; 158: 1013-8
19. Litaker DG, Solomon GD, Genzen JR. Impact of sumatriptan on clinic utilization and costs of care in migraineurs. Headache 1996; 36 (9): 538-41
20. Greiner DL, Addy SN. Sumatriptan use in a large group-model health maintenance organization. Am J Health Syst Pharm 1996; 53: 633-8
21. Caro JJ, Gestsios D. Pharmacoeconomic evidence and considerations for triptan treatment of migraine. Expert Opin Pharmacother 2002; 3 (3): 237-48
22. Adelman JU, Belsey J. Meta-analysis of oral triptan therapy for migraine: number needed to treat and relative cost to achieve relief within 2 hours. J Manag Care Pharm 2003; 9 (1): 45-52
23. Biddle AK, Shin YC, Kwong WJ. Cost-benefit analysis of sumatriptan tablets versus usual therapy for treatment of migraine. Pharmacotherapy 2000 Nov; 20 (11): 1356-64
24. Cady RK, Sheftell F, Lipton RB, et al. Economic implications of early treatment of migraine with sumatriptan tablets. Clin Ther 2001 Feb; 23 (2): 284-91
25. Caro G, Getsios D, Caro JJ, et al. Sumatriptan: economic evidence for its use in the treatment of migraine, the Canadian comparative economic analysis. Cephalalgia 2001 Feb; 21 (1): 12-9
26. Caro JJ, Getsios D, Raggio G, et al. Treatment of migraine in Canada with naratriptan: a cost-effectiveness analysis. Headache 2001 May; 41 (5): 456-64
27. Evans KW, Boan JA, Evans JL, et al. Economic evaluation of oral sumatriptan compared with oral caffeine/ergotamine for migraine. Pharmacoeconomics 1997; 12 (5): 565-77
28. Gross MLP, Dowson AJ, Deavy L, et al. Impact of oral sumatriptan 50mg on work productivity and quality of life in migraineurs. Br J Med Econ 1996; 10: 231-46
29. Halpern MT, Lipton RB, Cady RK, et al. Costs and outcomes of early versus delayed migraine treatment with sumatriptan. Headache 2002 Nov; 42 (10): 984-99
30. Joish V, Armstrong EP. Use of decision analysis in modeling the cost effectiveness of oral vs SC sumatriptan. Formulary 2000; 35 (6): 532-9
31. Lofland JH, Kim S, Batenhorst AS, et al. Cost effectiveness and cost benefit of sumatriptan in patients with migraine. Mayo Clin Proc 2001; 76: 1093-101
32. Reeder CE, Steadman S, Goldfarb SD. Economic comparison of oral triptans for management of acute migraine: implications for managed care. Am J Manag Care 2002 Feb; 8 (3 Suppl.): S80-4
33. Ferrari M, Roon K, Lipton RB, et al. Oral Triptans (serotonin 5-HT1B/1Dagonist) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001 Nov 17; 358: 1668-75
34. Sculpher M, Millson D, Meddis D, et al. Cost-effectiveness analysis of stratified versus stepped care strategies for acute treatment of migraine. Pharmacoeconomics 2002; 20 (2): 91-100
35. Lipton RB, Stewart WF, Stone A, et al. Stratified care vs step care strategies for migraine/the disability in strategies of care (DISC) study: a randomized trial. JAMA 2000 Nov; 284 (20): 2599-605
36. Wells N, Hettiarachchi J, Drummond M, et al. A cost-effectiveness analysis of eletriptan 40 and 80mg versus sumatriptan 50 and 100mg in the acute treatment of migraine. Value Health 2003 Jul-Aug; 6 (4): 438-47
37. Pryse-Phillips W. Comparison of oral eletriptan (40-80mg) and oral sumatriptan (50-100mg) for the treatment of acute migraine: a randomised, placebo-controlled trial in sumatriptan-naive patients [abstract]. Cephalalgia 1999; 19: 355
38. Williams P, Dowson AJ, Rapoport AM, et al. The cost effectiveness of stratified care in the management of migraine. Pharmacoeconomics 2001; 19 (8): 819-29
39. Clouse JC, Osterhaus JT. Healthcare resource use and costs associated with migraine in a managed healthcare setting. Ann Pharmacother 1994; 28: 659-63
40. O'Brien B, Goeree R, Streiner D. Prevalence of migraine headache in Canada: a population-based survey. Int J Epidemiol 1994 Oct; 23 (5): 1020-6
41. Lofland JH, Johnson NE, Batenhorst AS, et al. Changes in resource use and outcomes for patients with migraine treated with sumatriptan. Arch Intern Med 1999 Apr 26; 159: 857-63
42. Gold MR, Seigel JE, Russell LB, et al. Cost-effectiveness in health and medicine. 1st ed. New York: Oxford University Press, 1996
43. British National Formulary, London: London British Medical Association, 2002
44. Silberstein SD. Analyses of cost effectiveness of migraine therapies should consider multiple measures. J Manag Care Pharm 2003; 9 (3): 279-80
45. Lofland J, Pizzi L, Frick KD. A review of health-related lost workplace productivity instruments. Pharmacoeconomics 2004; 22 (3): 165-84
46. Gross MLP, Dowson AJ, Deavy L, et al. Impact of oral sumatriptan 50mg on work productivity and quality of life in migraineurs. Br J Med Econ 1996; 10: 231-46
47. Burton W, Conti D. The real measure of productivity. Bus Health 1999 Nov; 17 (11): 34-6
48. Johannesson M. The willingness to pay for health changes, the human-capital approach and the external costs. Health Policy 1996 Jun; 36 (3): 231-44
49. Koopmanschap MA, van Ineveld BM. Towards a new approach for estimating indirect costs of disease. Soc Sci Med 1992 May; 34 (9): 1005-10
50. Ferrari M. The economic burden of migraine to society. Pharmacoeconomics 1998; 13 (6): 667-76
51. Koopmanschap MA, Rutten FF, van Ineveld BM, et al. The friction cost method for measuring indirect costs of disease. J Health Econ 1995 Jun; 14 (2): 171-89
52. Lofland JH, Locklear JC, Frick KD. Different approaches to valuing the lost productivity of patients with migraine. Pharmacoeconomics 2001; 19 (9): 917-25